scientific program - World Allergy Organization

More documents

Recommendations

Info

Before prescribing, consult the full local prescribing information for complete details. Abridged summary of prescribing details SINGULAIR (montelukast sodium, MSD) is indicated in adult and pediatric patients 6 months of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated in adult and pediatric patients 2 years of age and older for the relief of daytime and nighttime symptoms of seasonal allergic rhinitis. Precautions - SINGULAIR should not be used to treat acute asthma attacks. Patients should be advised to have appropriate rescue medication available. SINGULAIR should not be abruptly substituted for inhaled or oral corticosteroids. The reduction in systemic corticosteroid dose in patients receiving anti-asthma agents including leukotriene receptor antagonists has been followed in rare cases by the occurrence of one or more of the following: eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy sometimes diagnosed as Churg-Strauss syndrome, a systemic eosinophilic vasculitis. Although a causal relationship with leukotriene receptor antagonism has not been established, caution and appropriate clinical monitoring are recommended when systemic corticosteroid reduction is considered in patients receiving SINGULAIR. SINGULAIR has not been studied in pregnant or nursing women and thus should not be used in these patients unless considered to be essential. The 4 and 5 mg chewable tablets of SINGULAIR contain aspartame, which is a source of phenylalanine (.842 mg phenylalanine per 5 mg chewable tablet and .647 mg phenylalanine per 4 mg chewable tablet). Interactions - SINGULAIR may be administered with other medications commonly used in the prophylaxis and chronic treatment of asthma and in the treatment of allergic rhinitis. *The area under the plasma concentration curve for SINGULAIR was decreased by approximately 40% when coadministered with phenobarbital. No dosage adjustment for SINGULAIR is recommended. Side effects - The overall incidence of side effects was comparable to placebo. In two similarly designed 12-week studies of asthma patients 15 years of age and older, only headache and abdominal pain were reported as drug related in ≥ 1% of patients and at a greater incidence than placebo. In an 8-week study of pediatric patients 6 to 14 years of age, only headache was reported as drug related in > 1% of patients and at a greater incidence than placebo. In a 12-week study of pediatric patients 2 to 5 years of age with asthma, only thirst was reported as a drug-related adverse experience in >1% of patients occurring at a greater incidence that placebo. In separate studies in allergic rhinitis in patients 2–14 years of age (2-week study) and adults 15 years of age and older (2- and 4-week studies), no drug related adverse experiences occurred in >1% of patients at a greater incidence that placebo. asthma & allergic rhinitis TWO RELATED CONDITIONS— ONE COMMON AIRWAY INTRODUCING YOUR ONE THERAPY FOR BOTH One Airway, One Approach, One Tablet SINGULAIR (montelukast sodium) is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. Copyright © 2003 Merck & Co., Inc. All rights reserved. 12-03 SGA 2003-W-6723-J Printed in USA VISIT US ON THE WORLD WIDE WEB AT http://www.merck.com
7:00 8:00 9:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00 23:00 Gold Satellite Symposium Opening Ceremony Welcome Reception WAO Congress–XVIII ICACI Final Program Breakfast Seminars Plenary Session Coffee Break Platinum Symposium Parallel Symposia Luncheon Seminars Grand Luncheon Seminar Gold Luncheon Symposium Poster Sessions Free Communication Sessions Meet the Professor Workshops Dinner Symposia * PROGRAM AT A GLANCE 7-12 September 2003 Sunday Monday Tuesday Wednesday Thursday Friday Debate of Day Parallel Symposium EXHIBIT HALL AND POSTER HALL OPEN 9:00 - 17:00 Breakfast Seminars Plenary Session Coffee Break Platinum Symposium Parallel Symposia Luncheon Seminars PhARF Awards & Luncheon Debate of Day Parallel Symposium Poster Sessions Free Communication Sessions Meet the Professor Workshops Breakfast Seminars Plenary Session Coffee Break Platinum Symposium Parallel Symposia Luncheon Seminars Grand Luncheon Seminar Debate of Day Platinum Symposium Congress Banquet Breakfast Seminars Plenary Session Coffee Break Platinum Symposium Parallel Symposia Luncheon Seminars Debate of Day Parallel Symposium All-Congress Event *Authors are present to discuss their posters from 15:45-17:00. However the posters are available to view each day from 9:00-17:00. The Scientific Program is subject to change. * EXHIBIT HALL AND POSTER HALL OPEN 9:00 - 17:00 * Poster Sessions Free Communication Sessions Meet the Professor Workshops EXHIBIT HALL AND POSTER HALL OPEN 9:00 - 17:00 Poster Sessions * Free Communication Sessions Meet the Professor Workshops EXHIBIT HALL AND POSTER HALL OPEN 9:00 - 17:00 Breakfast Seminars Plenary Session Coffee Parallel Break Symposia 29 Luncheon Seminars Parallel Symposia
Page 1: FINAL PROGRAM World Allergy Organiz
Page 4 and 5: 2 WAO Congress-XVIII ICACI Final Pr
Page 6 and 7: 4 World Allergy Organization (WAO)-
Page 8 and 9: 6 WAO Congress-XVIII ICACI Final Pr
Page 10 and 11: 8 sneezing runny nose itchy nose it
Page 12 and 13: 10 PRECAUTIONS (continued) ADVERSE
Page 14 and 15: 12 WAO Congress-XVIII ICACI Final P
Page 23 and 24: WAO Congress-XVIII ICACI Final Prog
Page 25 and 26: Whistler alpine resort WAO Congress
Page 29: XXIII EAACI Congress 12-16 June 200
Page 49 and 50: WEDNESDAY WEDNESDAY SEPTEMBER SEPTE
Page 51 and 52: www.annualmeeting.aaaai.org Visit w
Page 59 and 60: Presenting authors indicated in bol
Page 61 and 62: FRIDAY, 12 SEPTEMBER WAO Congress-X
Page 63 and 64: Imagine research targeting IgE, a k
Page 81 and 82:
WAO Congress-XVIII ICACI Final Prog
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 98 and 99:
96 PLAN TO ATTEND! SOYEZ DES NÔTRE
Page 100 and 101:
98 Dolovich, Myrna Canada BR86 Dubo
Page 102 and 103:
100 Schnuch, Axel Germany BR88 Scho
Page 104 and 105:
102 201 ACII - Journal of the World
Page 106 and 107:
104 WAO Congress-XVIII ICACI Final
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
114 Crowne Plaza Hotel Georgia 801
Page 118 and 119:
Page 120 and 121:
118 (salmeterol xinafoate/fluticaso
Page 122 and 123:
COPD, the most commonly reported dr
Page 124 and 125:
Page 126 and 127:
124 Seaplane landing at sunset Gran
Page 128:
DS2 - Dinner Symposium Monday, 8 Se
show all

scientific program - World Allergy Organization

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?